Skip to main content

Table 1 Eligibility criteria

From: Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson’s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial

Inclusion criteria  
Age between 30 and 80, regardless of gender  
For participants who are receiving anti-Parkinson treatment (levodopa preparations, dopamine agonists, monoamine oxidase inhibitors, catechins-o-methyl transferase (COMT) inhibitor, anticholinergic drugs, etc.), the dosage of the anti-Parkinson drug is requested to be relatively stable for at least 3 months before this clinical trial, and no plan has been made to change the existing treatment in the next 3 months  
Voluntarily participate and sign informed consent  
Exclusion criteria  
Patients with Parkinson Syndrome (PS) or Parkinsonism-Plus syndrome (PPS)  
Pregnant or lactating women, history of drug or alcohol abuse  
Severe cognitive impairment (Montreal Cognitive Assessment scale (MoCA) < 20 points), active depression or psychosis and/or under antidepressant or antipsychotic medication, severe sequelae of stroke and other systemic diseases affecting the heart, lung, liver or kidney  
Participating in other clinical studies or have participated in other clinical study within the previous 30 days